Diabetes Care April 2020 PMID 32041899

Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.

Chintan V Dave, Sebastian Schneeweiss, Deborah J Wexler, Gregory Brill, Elisabetta Patorno

Download social card

Mentions

Peak: 3 in Feb 2020

across 3 sources since Feb 2020

Extended reach

4,591

potential audience

Total likes

Video views

1,214

Mentions per month

Feb 2020 – Apr 2025

Where it's discussed

X / Twitter5 posts
News3 articles
YouTube1 videos

AI synopsis

What people are saying

The discussions reveal strong interest and moderate engagement, with posts highlighting the upward trend in prescribing specific medications, such as 'Trend up+9', and the importance of these trends as reflected in phrases like 'Trend new'. The tone and word choices suggest that readers see these findings as relevant and impactful for clinical practice and future research.

AgreementModerate agreement

Most contributors agree with the publication, referencing its importance and the observed trends, as seen in comments like 'Trend up' and mentions of increased prescriptions of certain drugs.

InterestHigh interest

The discussions show a high level of interest, with emphasis on the rising trends and implications for clinical practice, evident in phrases like 'Trend new' and 'Trend up+9'.

EngagementModerate engagement

Participants engage reasonably deeply, discussing prescribing patterns and policy influences, indicated by mentions of specific medication classes and the influence of guidelines.

ImpactModerate impact

The collective remarks suggest these findings could significantly influence clinical decisions and future research directions, as developers note changes in prescriber behaviors and drug preferences.

Abstract in brief

The study analyzed trends from 2013 to 2018 in the prescribing patterns and patient characteristics for SGLT2 inhibitors and GLP1 receptor agonists, using US-based claims data.
Empagliflozin's use increased significantly over five years, especially among patients with cardiovascular disease (CVD HF), while canagliflozin declined; similarly, dulaglutide's prescriptions grew, primarily replacing liraglutide, particularly among patients with CVD HF.
Most prescribers were internists or endocrinologists, with cardiologists prescribing less; changes in drug labels and guidelines influenced preferences for empagliflozin and dulaglutide, while factors like cost and ease of use also impacted prescribing choices.

Read the full abstract

All mentions

Advances in Managing Chronic Urethral Pain and Urinary Incontinence

This video discusses methods for managing chronic urethral pain and urinary incontinence, highlighting key treatments and recent scientific findings. It provides an overview of current therapeutic strategies and…

美聽 · Apr 30, 2025 1,214 views

maxkrish

@hscelebrities · X

Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018 https://t.co/eRo0QtZWUD

Apr 15, 2020 · 110 followers View post →

DR BRIJ MOHAN

@DRBRIJMOHAN1 · X

Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018 https://t.co/pQU9zzOycx

Mar 28, 2020 · 171 followers View post →

the paper link

@the_paper_link · X

Trend up+9: *Dave CV* et al (Diabetes Care) __Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018__ https://t.co/kOOQWTRtD3

Feb 16, 2020 · 136 followers View post →

the paper link

@the_paper_link · X

Trend new: *Dave CV* et al (Diabetes Care) __Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018__ https://t.co/kOOQWTRtD3

Feb 13, 2020 · 136 followers View post →

Dr.ドクター | 糖尿病専門医Youtuber

@Dr_doctor_DM · X

Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 20… https://t.co/Wnb97yD5iA

Feb 10, 2020 · 2,825 followers View post →